Key facts
- This page summarizes Michelle Yanez's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Mar 2024, 17:53.
Michelle Yanez - 26 Mar 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MIRA
- Reported as of
- 26 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2024, 17:53:43 UTC
- Prior SEC filing
- 21 Aug 2023
- Next SEC filing
- 16 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Yanez
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michelle Yanez filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 21 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRA
transaction
Derivative
Incentive Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 57,799
- Date
- 26 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $1.15
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on March 26, 2024.
Footnote F2
The options were granted under the Issuer's 2022 Amended and Restated Omnibus Incentive Plan (the "Plan") whereby 50% of such incentive options, or 75,000 options, will vest on the six month anniversary of the of the grant, or September 26, 2024, and the remaining 50% will vest on the first anniversary of the grant date, March 26, 2025.
Footnote F3
Represents (i) 3,334 stock options that were issued to the Reporting Person under the Plan that became exercisable on June 15, 2022 at an exercise price of $5.00 (ii) 3,333 stock options that were issued to the Reporting Person under the Plan that became exercise on June 15, 2023 at an exercise price of $5.00 each, (iii) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which vested in full on April 28, 2024 at an exercise price of $6.50 each, (iv) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which will vest in full on April 28, 2024 at an exercise price of $6.50 each (v) 20,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each.